BioCryst Pharmaceuticals, Inc. ROE

ROE of BCRX for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2021 was 291.59% (a -115.14% decrease from previous year)
  • Annual ROE for 2020 was -1925.37% (a 673.43% increase from previous year)
  • Annual ROE for 2019 was -248.94% (a 63.5% increase from previous year)
  • Twelve month ROE ending September 30, 2022 was 99.23% (a -24.43% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -65.97% year-over-year
Trailing ROE for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
99.23% 131.31% 162.18% 291.59%
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of BioCryst Pharmaceuticals, Inc.

Most recent ROEof BCRX including historical data for past 10 years.

Interactive Chart of ROE of BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 291.59%
2020 -1925.37%
2019 -248.94%
2018 -152.26%
2017 -154.16%
2016 -223.7%
2015 -69.75%
2014 -121.3%
2013 3811.14%
2012 -544.61%

Business Profile of BioCryst Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology